Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) - Dec 17, 2024 - P1 | N=18 | ReSPECT-LM (NCT05034497) | Sponsor: Plus Therapeutics | "...multiple-dose expansion trials planned in 2025...Key Highlights...Nine of 20 patients with LM primary breast cancer were treated and evaluable through five dose escalation cohorts, with the maximum tolerated dose yet to be reached...Circulating tumor cell (CTC) and radiographic (MRI) response data were available for 8 of the 9 breast cancer patients with LM, and clinical response data were available for 7 of the 9 patients...Best response rates (response only) were: CTC: 88% (7/8); MRI imaging: 25% (2/8); Clinical: 29% (2/7)...Clinical benefit rates (response and stable disease) were: CTC: 100% (8/8); MRI imaging: 75% (6/8); Clinical: 71 % (5/7)...Median overall survival for 9 breast cancer patients was 9 months....Initiate ReSPECT-LM Phase 1b single-dose breast expansion cohort in Q1 2025 to further evaluate single-dose safety and efficacy of Rhenium (186Re) Obisbemeda."
New trial • P1 data • Trial status • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Triple Negative Breast Cancer
|